7-13-07

Express Mail Label No. EM 086871259 US Dated: July 12, 2007

JW#

Docket No.: 2001377.123-US1

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

**Gregor CEVC** 

Confirmation No.:

2670

Application No.:

09/284,683

Art Unit:

1615

Filed:

June 24, 1999

Examiner:

G. S. Kishore

Title:

PREPARATION FOR THE TRANSPORT OF AN ACTIVE

SUBSTANCE ACROSS BARRIERS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98, the Examiner's attention is invited to the attached Form PTO/SB/08, listing references AW1-AZ1, AA2-AZ2, AA3, BS-BZ, BA1-BF1, CK-CZ, CA1-CZ1 and CA2-CI2 and to the attached copy of references BS-BZ, BA1-BF1, CK-CZ, CA1-CZ1 and CA2-CI2. It is respectfully requested that the Examiner review the listed references and make them of record by initialing and returning a copy of the enclosed Form PTO/SB/08 with the next Patent Office communication.

This Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits and before the mailing date of a final Office Action or a Notice of Allowance.

07/13/2007 TMBUYEN2 00000040 080219 09284683

01 FC:1806

180.00 DA

Application No.: 09/284,683 Docket No.: 2001377.00123US1

Please charge the required fee, estimated to be \$180.00, to our Deposit Account No. 08-0219.

Dated: July 12, 2007

Respectfully submitted,

Matthew E. Langer

Registration No.: 36,343

Wilmer Cutler Pickering Hale and Dorr LLP 399 Park Avenue New York, New York 10022 (212) 230-8800 (telephone) (212) 230-8888 (facsimile)

Used in Lieu of PTO/SB/08A/B (Based on PTO 04-07 version)

Complete if Known Substitute for form 1449/PTO **Application Number** 09/284,683-Conf. #2670 **INFORMATION DISCLOSURE** Filing Date June 24, 1999 STATEMENT BY APPLICANT First Named Inventor **Gregor CEVC** 1615 Art Unit (Use as many sheets as necessary) G. S. Kishore Examiner Name 2001377.00123US1 Sheet Attorney Docket Number

			U.S. PATE	NT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AW1*	US-2001/0012849	08-09-2001	Wechter	
	AX1*	US-2002/0003179	01-10-2002	Verhoff et al.	
	AY1*	US-2002/0012680	01-31-2002	Patel et al.	
	AZ1*	US-2002/0037877	03-28-2002	Singh	
	AA2*	US-2002/0048596	04-25-2002	CEVC	
	AB2*	US-2002/0106345	08-08-2002	Uhrich et al.	
	AC2	US-2002/0119188	08-29-2002	Niemiec et al.	
	AD2*	US-2002/0147238	10-10-2002	Jerussi et al.	
	AE2*	US-20040071767-A1	04-15-2004	Cevc et al.	
	AF2*	US-20070031483	02-08-2007	Cevc	
	AG2*	US-20070042030-A1	02-22-2007	Cevc	
	AH2*	US-4,369,182	01-18-1983	Ghyczy et al.	•
	AI2*	US-4,849,224	07-18-1989	Chang et al.	
	AJ2*	US-4,937,182	06-26-1990	Hancock et al.	
	AK2*	US-4,937,254	06-26-1990	Sheffield et al.	·
	AL2*	US-4,983,395	01-08-1991	Chang et al.	
	AM2*	US-5,202,125	04-13-1993	Ebert et al.	
	AN2*	US-5,209,720	05-11-1993	Unger	
	AO2*	US-5,244,678	09-14-1993	Legros et al.	
	AP2*	US-5,460,820	10-24-1995	Ebert et al.	
	AQ2*	US-5,585,109	12-17-1996	Hayward et al.	
	AR2*	US-5,614,178	03-25-1997	Bloom et al.	
	AS2*	US-5,681,849	10-08-1997	Richter et al.	
	AT2*	US-5,783,208	07-21-1998	Venkateshwaran et al.	
	AU2*	US-5,874,095	02-23-1999	Deckner et al.	
	AV2*	US-5,891,472	04-06-1999	Russell	
	AW2*	US-6,277,892	08-21-2001	Deckner et al.	
	AX2*	US-6,577,880	06-10-2003	Ishida et al.	
	AY2*	US-6,797,276	09-28-2004	Glenn et al.	
	AZ2*	US-6,868,686-A1	03-22-2005	Ueda et al.	
	AA3*	US-RE 33273		Speaker	

		FOREIG	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
	BS	JP-2006131597 (English Language Abstract)	05-02-2006	Hisamitsu Pharmaceut CO inc		
	вт	WO-90/09385	08-23-1990	The Liposome Company Inc		
	BU	WO-90/11065	10-04-1990	Theratech, Inc.		
	BV	WO-91/01146	02-07-1991	Praxis Biolog Inc		
	BW	WO-92/04009	03-19-1992	Univ London Pharmacy		oxdot
	вх	WO-96/19205	06-27-1996	Theratech, Inc.		
	ВҮ	WO-98/24407 (English Language Abstract)	06-11-1998	L'Oreal		

The state of the s		
Examiner	Date	
Signature	Considered	

Complete if Known Substitute for form 1449/PTO 09/284,683-Conf. #2670 **Application Number** INFORMATION DISCLOSURE Filing Date June 24, 1999 First Named Inventor **Gregor CEVC** STATEMENT BY APPLICANT Art Unit 1615 (Use as many sheets as necessary) Examiner Name G. S. Kishore 2001377.00123US1 Attorney Docket Number Sheet

E	3Z	WO-00/44349	08-03-2000	IDEA AG	
E	3A1	WO-01/000247	01-04-2001	The Liposome Company, Inc	
	3B1	WO-02/32398	04-25-2002	KOHANE, et al	
E	3C1	WO-02/058670	08-01-2002	CHASIN, et al	
E	3D1	WO-04/032900	04-22-2004	IDEA AG	
E	3E1	WO-05/063213	07-14-2005	Biodelivery Sciences International, Inc	
E	3F1	WO-06/050926	05-18-2006	IDEA AG	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). \*2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \*3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*6 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*4 Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.1	clude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (boo magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	СК	Almeida et al., "Nasal delivery of vaccines," Journal of Drug Targeting, Vol 3, No 6, pp. 455-67 (1996)			
	CL	Byas-Smith et al., "Transdermal clonidine compared to placebo in painful diabetic neuropathy using two stage 'enriched enrollment' design," Pain, Vol 60, pp. 267-274 (1995)			
	СМ	Castillo et al., "Glucocorticoids Prolong Rat Sciatic Nerve Blockade In Vivo from Bupivacaine Microspheres," Anesthesiology, Vol 85, No 5, pp. 1157-66 (1996)			
	CN	Cevc et al., "Phospholipids handbook", Marcel Dekker, Inc., New York, Basel, Hong Kong, pp. 375-376 and 404 (1993)			
	со	Claims filed February 4, 2003, in connection with U.S. Patent Application No. 10/357,617 (U.S. Patent Publication No. US 2004/0071767 A1), under examination by Examiner Kishore of the USPTO.			
	СР	Claims filed October 20, 2006, in connection with U.S. Patent Application No. 10/357,617 (U.S. Patent Publication No. US 2004/0071767 A1), under examination by Examiner Kishore of the USPTO.			
	ca	Claims filed January 22, 2007, in connection with U.S. Patent Application No 10/037,480 (U.S. Patent Publication No. US 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO			
	CR	Claims filed March 20, 2006, in connection with U.S. Patent Application No 10/037,480 (U.S. Patent publication No. US 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO			
	cs	Claims filed September 21, 2005, in connection with U.S. Patent Application No. 10/037,480 (U.S. Patent Publication No. US 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO			
	СТ	Claims filed October 20, 2004, in connection with U.S. Patent Application No 10/037,480 (U.S. patent Publication No. US 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO			
	CU	Claims filed January 4, 2002, in connection with U.S. Patent Application No 10/037,480 (U.S. Patent Publication No. US 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO			
	cv	Claims filed February 26, 2007, in connection with U.S. Patent Application No. 10/984,450			

Examiner	 Date	
Signature	Considered	<u> </u>

Complete if Known Substitute for form 1449/PTO Application Number 09/284,683-Conf. #2670 **INFORMATION DISCLOSURE** Filing Date June 24, 1999 STATEMENT BY APPLICANT First Named Inventor **Gregor CEVC** Art Unit 1615 (Use as many sheets as necessary) Examiner Name G. S. Kishore Attorney Docket Number 2001377.00123US1 Sheet 4

	(U.S. Patent Publication No US 2005/0123897 a1), under examination by Examiner Fortuna of the USPTO	
CW	Claims filed May 31, 2006, in connection with U.S. Patent Application No 10/984,450 (U.S. Patent Publication No US 2005/0123897 A1), Under examination by Examiner Fortuna of the USPTO	
СХ	Claims filed May 31, 2005, in connection with U.S. Patent Application No 10/984,450 (U.S. Patent Publication No US 2005/0123897 A1), under examination by Examiner Fortuna of the USPTO	
СҮ	Claims filed May 12, 2004, in connection with U.S. Patent Application No. 10/357,618 (U.S. Patent Publication No. 2004/0105881 A1), under examination by Examiner Ghali of the USPTO	
CZ	Claims presently pending in U.S. Patent Application No 09/890,335, under examination by Examiner Gangle of the USPTO	
CA1	Claims presently pending in U.S. Patent Application No 09/890,371, under examination by Examiner Hissong of the USPTO	
CB1	Copy of International Search Report for International Patent Application No. PCT/EP2005/011986. (July 4, 2006).	
CC1	Definition of Microbicide, Wikipedia, The Free Online encyclopedia (2007)	
, CD1	Edwards, et al., Effects of Triton X-100 on Sonicated Lecithin Vesicles, Langmuir, Vol. 5, pages 472-475 (1989).	
CE1	Frantzen et al., " Assessing the accuracy of routine Photon Correlation Spectroscopy Analysis of Heterogeneous Size Distributions," AAPS PharmSciTech, Vol 4, No 3, Article 36, pp. 1-9 (2003)	
CF1	Glen et al, "Skin immunization made possible by cholera toxin 'letter!", Nature, GB, MacMillan Journal LTD., London, Vol 391, no 6670, pp. 851 (Feb 1998)	
CG1	Golden et al., "Role of Stratum Corneum Lipid Fluidity Transdermal Drug Flux," on Journal of Pharmaceutical Sciences Vol. 76, No. 1, January 1987, American Pharmaceuticals Association, pp. 25-28.	
CH1	Grahame R, "Transdermal non-steroidal anti-inflammatory agents," BJCP, Vol 49, No1, pp. 33-35 (Jan-Feb 1995)	
CI1	Holzbach RT, "Detection of Vesicles in native and model Biles by Morphological and other structural Techniques: applications and limitations," Hepatology, Sep12 (3 Pt 2), pp. 106S-112S (1990)	
CJ1	Ito, Yoshimasa et al. "Percutaneous Absorption of Acemetacin from a Membrane Controlled Transdermal System and Prediction of the Disposition of the Drug in Rats." Biol. Pharm. Bull., 16(6):583-588. (1993).	
CK1	Lehmann, J. et al. "Analgesic and anti-inflammatory efficacy of IDEA-070 in UVB-induced sunburn." Journal of the European Academy of Dermatology and Venereology, 18(S2):167-168. (October 2004).	
CL1	Merck Index: 10th Edition. pp. 779-780. (1983).	
CM1	Office Action issued April 11, 2007, in connection with U.S. Patent Application No. 10/037,480 (U.S. Patent Publication No. US 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO.	
CN1	Office Action issued December 19, 2005, in connection with U.S. Patent Application No. 10/037,480 (U.S. Patent Publication No. US 2003/0099694 A1), under examiner by Examiner Fortuna of the USPTO	
CO1	Office Action issued December 28, 2006, in connection with U.S. Patent Application No. 10/357,618 (U.S. Patent Publication No. 2004/0105881 A1) under examination by Examiner Ghali of the USPTO.	

Examiner	•	Date	
Signature		Considered	

Sub	estitute for form 1449/PTO				Complete if Known	
				Application Number	09/284,683-Conf. #2670	
11	<b>NFORMATION</b>	l Di	SCLOSURE	Filing Date	June 24, 1999	
S	TATEMENT B	3Y /	APPLICANT	First Named Inventor	Gregor CEVC	
				Art Unit	1615	
	(Use as many sh	eets as	necessary)	Examiner Name	G. S. Kishore	
Sheet	Sheet 4 of 4		4 Attorney Docket Number 2001377.00123US1		2001377.00123US1	

CP1	Office Action issued January 19, 2007, in connection with U. 10/357,617 (U.S. Patent Publication No. US 2004/0071767 Examiner Kishore of the USPTO.					
CQ1	Office Action issued March 30, 2005, in connection with the 10/037,480 (U.S. Patent Publication No U.S. 2003/0099694 Examiner Fortuna of the USPTO					
CR1	Office Action issued May 30, 2006, in connection with U.S. F (U.S. Patent Publication No. US 2004/0071767 A1), under e of the USPTO.					
CS1	Office Action issued on August 28, 2006, in connection with 10/984,450 (U.S. Patent Publication No US 2005/0123897 A Examiner Fortuna of the USPTO	U.S. Patent A A1), under exa	pplication No mination by the			
CT1	Office Action issued on February 7, 2006, in connection with 10/984,450 (U.S. Patent Publication No US 2005/0123897 A Examiner Fortuna of the USPTO					
CU1	Office Action issued on May 16, 2007, in connection with U. 10/984,450 (U.S. Patent Publication No. US 2005/0123897 Examiner Fortuna of the USPTO.					
CV1	Office Action issued on October 16, 2003, in connection with 10/037,480 (U.S. Patent Publication No US 2003/0099694 A Examiner Fortuna of the USPTO	n U.S. Patent A 1), under exa	Application No mination by			
CW1	Office Action issued September 20, 2006, in connection with 10/037,480 (U.S. Patent Publication No US 2003/0099694 A Examiner Fortuna of the USPTO	n U.S. Patent A 1), under exa	Application No. mination by			
GX1	Ogiso, Taro et al. "Membrane-Controlled Transdermal Thera Clonazepam and Anticonvulsant Activity after its Application 449. (1989).					
CY1	Paul et al., "Non Invasive administration of protein antigens: transdermal immunization with bovine serum albumin in transfersomes," Vaccine Research, Vol 4, No 3, pp. 145-164 (1995)					
CZ1	Paul et al., "Transdermal immunisation with an integral mem protein, by means of ultradeformable drug carriers, transfers pp. 188-195 (Jan 1998)	nbrane compo	nent, gap junction			
CA2	Price, "A Review of the Factors Influencing the Penetration Leaves," I.C.I. Ltd, Plant Protection Division, Jealott's Hill Reservishing RG12 6EY, UK, pgs. 237-252.					
CB2	Product Information, "Polysorbate 80 VG" (2004)					
CC2	Product Information, "Tween 80 Pure" (2004)					
CD2	Ranade V., "Drug Delivery Systems.6. Transdermal Drug Delivery," J. Clin Pharmacol, Vol 31, pp. 401-418 (1991)					
CE2	Swenson, E. Scott and William J. Curatolo. "Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity." Advanced Drug Delivery Reviews, 8:39-92. (1992).					
CF2	Trotta, M. et al. "Deformable liposomes for dermal administration of methotrexate."  International Journal of Pharmaceutics, 270:119-125. (February 11, 2004).					
CG2	Trotta, M. et al. "Elastic liposomes for skin delivery of dipota International Journal of Pharmaceutics, 241(2):319-327. (Ju	issium glycyrd ily 25, 2002).	nizinate."			
CH2	Wess, L. "Down, down, deeper and down." Biocentury, The 12(22):A11-A12. (May 17, 2004).	Bernstein Re				
CI2	Yuan, et al., "Cationic Liposome and Gene Transfer," Progra 28(2), pp. 163-165, 1997.	ess in Physiol	ogical Science,			
Examiner Signature		Date Considered				